SAB Biotherapeutics Inc.
SABS | NASDAQ
$3.48
+$0.09 (+2.65%)
Sep 22, 2026, 10:45 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Cash & Equivalents | 10.5M | 8.9M | 56.57M | 15.05M | 33.21M | 12.61M |
Short-Term Investments | 86.09M | 11.86M | n/a | n/a | n/a | n/a |
Long-Term Investments | 46.89M | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 5.46M | 482.1K | 350.23K | 467.69K | -1 | n/a |
Receivables | 946.78K | 54.96K | n/a | 5.56M | 8.01M | 20.57M |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 3.51M | 2.98M | n/a | n/a | 6.34M | n/a |
Total Current Assets | 101.05M | 23.79M | 58.91M | 22.1M | 50.19M | 34.46M |
Property-Plant & Equipment | 19.4M | 19.92M | 24.68M | 28.34M | 30.95M | 22.08M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 71.76M | 20.4M | 25.03M | 28.81M | 30.95M | 22.08M |
Total Assets | 172.81M | 44.2M | 83.94M | 50.9M | 81.14M | 56.54M |
Account Payables | 3.15M | 1.69M | 945.93K | 3.68M | 4.46M | 7.38M |
Deferred Revenue | n/a | n/a | 1.32M | n/a | 100K | 100K |
Short-Term Debt | 951.37K | 275.85K | 1.05M | 772.67K | 1.8M | 538.73K |
Other Current Liabilities | 1.55M | n/a | 4.49M | 8.1M | 8.7M | 1.17M |
Total Current Liabilities | 10.68M | 7.98M | 10.81M | 14.99M | 26.46M | 11.06M |
Long-Term Debt | n/a | n/a | n/a | 541.64K | n/a | 172.04K |
Other Long-Term Liabilities | 5.64M | 6.39M | 11.77M | 320.93K | 10.72M | n/a |
Total Long-Term Liabilities | 10.63M | 10.25M | 15.83M | 4.85M | 16.14M | 6.47M |
Total Liabilities | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M | 17.53M |
Total Debt | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M | 8.13M |
Book Value | 151.49M | 25.97M | 57.3M | 31.06M | 38.55M | 39.01M |
Book Value Per Share | 2.47 | 2.80 | 10.38 | 7.14 | 14.10 | 14.44 |
Common Stock | 4.77K | 935 | 929 | 5.09K | 4.35K | 3.52K |
Retained Earnings | -110.9M | -124.17M | -90.06M | -47.87M | -29.13M | -11.98M |
Comprehensive Income | 186.51K | -135.41K | 26.42K | n/a | n/a | n/a |
Shareholders Equity | 151.49M | 25.97M | 57.3M | 31.06M | 38.55M | 39.01M |
Total Investments | 132.98M | 11.86M | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove SABS